Private EquityScreenerRefer

MARKET INSIGHTS

  • EventsNEWPrivate market milestones
  • NewsPrecize daily pulse
  • BlogsIn-depth articles and opinions

GUIDES

Explore Now
  • Unlisted SharesStep-by-step · KYC
  • BuyingStep-by-step · KYC
  • SellingExit in 24 - 48 hours
  • Pre-IPOReturns · risks · case studies
  • Tax GuideBudget 2026 changes
  1. Home
  2. Unlisted share news
  3. Lord’s Mark Industries Ltd – ₹200 Crore Rights Issue & ESOP Approval Po…

Lord’s Mark Industries Ltd – ₹200 Crore Rights Issue & ESOP Approval Post NCLT Scheme

6 Jan 2026

Add as preferred source
Key Takeaways

Key Takeaway:

  • The combination of NCLT‑driven capital reset, sizeable rights issue, and targeted ESOP for healthcare expansion suggests Lord’s Mark is positioning for a cleaner balance sheet and growth relisting story; actual investor appeal will depend on rights pricing, post‑merger financials, and execution in the new renal/med‑tech verticals once trading resumes on BSE.


Key Takeaway:

  • The combination of NCLT‑driven capital reset, sizeable rights issue, and targeted ESOP for healthcare expansion suggests Lord’s Mark is positioning for a cleaner balance sheet and growth relisting story; actual investor appeal will depend on rights pricing, post‑merger financials, and execution in the new renal/med‑tech verticals once trading resumes on BSE.


Lords Mark Industries

Lords Mark Industries

0.00%

Expert Analysis

Expert Analysis:

  • Lord’s Mark Industries’ fifth Monitoring Committee meeting (3 Jan 2026) approved a rights issue of up to ₹200 crore, to be launched after BSE trading resumes, with promoters allowed to renounce their rights in favour of other investors, signalling intent to broad‑base the shareholder base alongside growth funding.​

  • The committee reviewed NCLT‑ordered capital restructuring, including allotment of 42.66 crore shares at a 1.25:1 swap ratio to eligible shareholders of Lord’s Mark Industries Pvt Ltd and extinguishment of ex‑promoter holdings plus up to 5% proportionate reduction in large public holdings, aimed at cleaning up and realigning the capital structure before relisting.​

  • A new ESOP pool of at least 2% of equity (on the 42.66 crore share base) was cleared to attract senior talent for the company’s push into renal care and med‑tech (via RenalX acquisition, AI‑based dialysis machines and remote monitoring platform), indicating a pivot toward higher‑tech, higher‑margin healthcare businesses.​

Publisher:SCANX